Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00399646
Other study ID # revJ060707
Secondary ID
Status Completed
Phase Phase 2
First received November 14, 2006
Last updated May 11, 2009
Start date November 2005
Est. completion date March 2009

Study information

Verified date May 2009
Source Neovasc Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the Metricath Gemini System is to pre-dilate the target treatment area, take arterial lumen measurements in a native section of artery or within the deployed stent and perform further dilation of the deployed stent if required. In this manner, the Metricath Gemini System can assist the Interventionalist by providing arterial measurements prior to stenting, performing pre-stenting angioplasty, taking within stent measurements to help determine if the stent is fully deployed, and by performing post-stenting dilations to further dilate the stent if required.


Description:

Several recent clinical studies have suggested that proper vascular stent deployment directly affects clinical outcome, and the rate of re-stenosis. These studies suggest that angiography alone is not sufficient to ensure proper vascular stent deployment, and that re-stenosis rates will decline if proper stent apposition has occurred. The importance of proper stent sizing and apposition is further emphasised with the increasing use of drug eluting stents, the drug effects of which are only realized upon contact with the arterial wall.

Angiometrx Inc. developed the Metricath Arterial Measurement System in response to the need for increased stent sizing and deployment. The Metricath System measures the diameter and cross sectional area of arteries using an intravascular balloon catheter attached to a computerized console. Considering the ease and rapidity of obtaining Metricath results, this technique may form an alternative to evaluate vessel area and stent expansion.

The Metricath System was 510(k) cleared in the U.S. in June, 2003, and received European and Canadian market approvals in 2004.

Angiometrx Inc. has now developed the next generation of Metricath System, which incorporates a second balloon on the catheter, intended for angioplasty purposes. The Metricath Gemini System is comprised of a dual balloon catheter which is attached to the same Metricath computerized console as the Metricath System. As with the Metricath System, the Metricath Console operates the inflation and deflation of the Gemini measurement balloon and provides arterial cross-sectional area and diameter. The Metricath Gemini angioplasty balloon is controlled separately in the traditional manner using a hand-held inflation device, attached to a port in the hub of the catheter.


Recruitment information / eligibility

Status Completed
Enrollment 145
Est. completion date March 2009
Est. primary completion date November 2007
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients in whom coronary artery angiography is indicated and angioplasty and stenting is being considered.

- Single vessel disease of an artery with a lesion assessable to standard coronary guidewires and are scheduled or indicated for percutaneous coronary intervention.

- A maximum of one lesion requiring treatment (angioplasty +/- stenting) to an intended arterial diameter of 2.5 mm - 4.0 mm.

- Target stent length of 15 mm - 32 mm, where a single stent can adequately cover the lesion.

- Stenotic de novo lesions in native coronary arteries.

Exclusion Criteria:

- Women who are pregnant.

- Participation in a study involving investigational drugs or devices during the last six months.

- Patients with previous stenting in the target vessel area.

- Patients who experienced a myocardial infarction, Braunwald Class C, and very unstable Braunwald Class B3 within 6 weeks prior to the procedure or have unstable angina pectoris.

- Patients who are experiencing TIA's or minor or major strokes within six months prior to procedure.

- Contraindicated for antiplatelet and/or anticoagulation medications.

- Symptoms of cardiogenic shock.

- Patients who underwent a staged procedure 30 days prior to enrolment and/or were scheduled to have a staged procedure 14 days after treatment.

- Significant liver or kidney disease or malignancy.

- Patients scheduled for any other surgery or other procedure within 30 days.

- Severe peripheral vascular disease preventing femoral access.

- Left ventricle ejection fraction of < 35%.

- Total occlusion of target vessel.

- A blood pressure in excess of 180 mmHg at the time of the angiography.

- Visible thrombus, filling defect, or ulceration in the target artery.

- Severely calcified lesions which suggest that balloon pre-dilatation will not achieve adequate luminal diameter to allow successful stent delivery and deployment.

- The target lesion is beyond a left main artery stenosis > 50%.

- Contraindicated for CABG.

- Coronary spasm in the absence of a significant stenosis.

- Requiring treatment of more than two lesions.

- Requiring treatment with atherectomy.

- Lesions in surgical conduits - saphenous vein grafts, internal mammary arteries, or radial arteries.

- Unprotected left main coronary artery.

- Diffuse disease.

- Excessive tortuosity of proximal segment.

- Extremely angulated segments > 90°.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Metricath Gemini System


Locations

Country Name City State
Canada St. Paul's Hospital Vancouver British Columbia
Canada Vancouver Hospital Vancouver British Columbia
Netherlands Amphia Hospital Breda The Netherlands
Netherlands Leiden University Medical Center Leiden The Netherlands
Netherlands Medisch Centrum Rijmond Zuid Rotterdam The Netherlands
Netherlands University Medical Center Rotterdam Rotterdam The Netherlands
United States Sinai Hospital Baltimore Maryland
United States Duke University Medical Center Durham North Carolina
United States Pasco Cardiology Center Hudson Florida
United States Baptist Miami Hospital Miami Florida
United States Columbia Presbyterian Hospital New York New York
United States University of Oklahoma Oklahoma City Oklahoma
United States UC Irvine Medical Center Orange California
United States Mercy Heart Institute Sacramento California
United States Florida Cardiovascular Institute Tampa Florida
United States Tyler Cardiovascular Consultants Tyler Texas

Sponsors (1)

Lead Sponsor Collaborator
Neovasc Inc.

Countries where clinical trial is conducted

United States,  Canada,  Netherlands, 

References & Publications (6)

Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307-10. — View Citation

Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van De Werf FJ, Weintraub WS, Mitchell KR, Morrisson SL, Brindis RG, Anderson HV, Cannom DS, Chitwood WR, Cigarroa JE, Collins-Nakai RL, Ellis SG, Gibbons RJ, Grover FL, Heidenreich PA, Khandheria BK, Knoebel SB, Krumholz HL, Malenka DJ, Mark DB, Mckay CR, Passamani ER, Radford MJ, Riner RN, Schwartz JB, Shaw RE, Shemin RJ, Van Fossen DB, Verrier ED, Watkins MW, Phoubandith DR, Furnelli T. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001 Dec;38(7):2114-30. — View Citation

de Jaegere P, Mudra H, Figulla H, Almagor Y, Doucet S, Penn I, Colombo A, Hamm C, Bartorelli A, Rothman M, Nobuyoshi M, Yamaguchi T, Voudris V, DiMario C, Makovski S, Hausmann D, Rowe S, Rabinovich S, Sunamura M, van Es GA. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J. 1998 Aug;19(8):1214-23. — View Citation

Fitzgerald PJ, Oshima A, Hayase M, Metz JA, Bailey SR, Baim DS, Cleman MW, Deutsch E, Diver DJ, Leon MB, Moses JW, Oesterle SN, Overlie PA, Pepine CJ, Safian RD, Shani J, Simonton CA, Smalling RW, Teirstein PS, Zidar JP, Yeung AC, Kuntz RE, Yock PG. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. Circulation. 2000 Aug 1;102(5):523-30. — View Citation

Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr; American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty); Society for Cardiac Angiography and Interventions. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation. 2001 Jun 19;103(24):3019-41. — View Citation

van der Giessen WJ, Regar E, McFadden E, McDougall I, Serruys PW. Assessment of stent dimensions with a novel intracoronary balloon-based system: comparative study versus intravascular ultrasound and quantitative coronary angiography. The CAMUS - Coronary Angioplasty Metricath vs. UltraSound Trial. EuroIntervention. 2005 Aug;1(2):244-51. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To observe the safety of the device, as determined by freedom from MACE (major adverse cardiac events) within 30 days post-procedure. 30 days Yes
Primary To observe the success of the device as determined by residual diameter stenosis 30 days No
Primary To evaluate the inflation of dilation balloon to desired pressure immediate No
Secondary To evaluate the successful delivery of catheter to target area immediate No
Secondary To evaluate the performance of the device to measure arterial size immediate No
See also
  Status Clinical Trial Phase
Completed NCT02837744 - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed NCT02214082 - Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention N/A
Recruiting NCT00370578 - Aspiration Device in Myocardial Infarction Trial N/A
Recruiting NCT02276846 - Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT N/A
Recruiting NCT01080638 - Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction. Phase 4
Completed NCT03673254 - Evaluation of Practices and Prognostic Factors of Percutaneous Coronary Interventions (PCI) of Calcified Complex Lesions Using Rotational Atherectomy Device.
Completed NCT01249027 - XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Completed NCT01180517 - The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations Phase 4
Recruiting NCT05113407 - Observatory on the Use of the Shockwave Medical C2 Coronary Lithotripsy System in the General Population in France.
Completed NCT04445480 - Popliteal Block for Lower Limb Angioplasty N/A
Completed NCT02722213 - Mindfulness & Stress Management Study for Cardiac Patients N/A
Completed NCT00858715 - Resistance to Antithrombotic Therapy N/A
Recruiting NCT04325867 - Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19 N/A
Completed NCT01174472 - Drug Eluting Balloon Angioplasty for Dialysis Access Treatment Phase 2/Phase 3
Terminated NCT00289601 - Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty Phase 4
Completed NCT00715416 - PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents Phase 4
Terminated NCT00437905 - Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Phase 4
Completed NCT01894152 - XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Completed NCT00808717 - Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI) Phase 4
Completed NCT03388892 - Drug-Eluting Balloon in Arteriovenous Graft N/A